ARTICLE | Company News
PharmAthene, NIH infectious news
September 29, 2014 7:00 AM UTC
PharmAthene received a contract worth up to $28.1 million from NIH's National Institute of Allergy and Infectious Disease (NIAID) to develop its preclinical thermostable anthrax vaccine based on the ...